The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Targeted therapy versus standards of care in metastatic NSCLC
Benjamin Besse, MD, PhD, Gustave Roussy Cancer Institute, Paris, provides an overview of the Phase II randomized UNICANCER/IFCT1301-SAFIR02-LUNG intergroup trial (NCT02117167) comparing targeted therapy to standard of care (SoC) in patients with metastatic non-small cell lung cancer (NSCLC). 175 patients either received eight possible targeted therapies or the SoC, which mainly consisted of pemetrexed therapy, and targeted therapies failed to reach the primary and secondary endpoints of progression-free survival (PFS) and overall survival (OS) respectively. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
